Waldenstrom's Macroglobulinemia Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia
This study evaluated the efficacy and safety of ibrutinib-rituximab in Japanese patients with WM. Patients received ibrutinib 420 mg orally once daily plus weekly rituximab 375 mg/m2 IV (8 infusions total). The primary end point was major response rate (MRR; PR or better) by Independent Review Committee assessment. Secondary endpoints were progression-free survival (PFS), safety, pharmacokinetics, and biomarkers. Primary analysis was conducted in 16 patients [baseline, treatment naïve: 8 (50.0%); relapsed/refractory WM: 8 (50.0%)] who received ibrutinib-rituximab, after all patients completed Week 57 or end of treatment. ...
Source: International Journal of Hematology - April 10, 2024 Category: Hematology Authors: Koji Izutsu Hisashi Kato Naohiro Sekiguchi Tomoaki Fujisaki Toshiro Kawakita Naoshi Obara Kosei Matsue Mitsutaka Nishimoto Tomoyoshi Hatayama Mitsuo Inagaki Ei Fujikawa Source Type: research

Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenstr öm Macroglobulinemia
AbstractPurpose of ReviewThe treatment of Waldenstr öm macroglobulinemia (WM) has evolved over the past decade. With the seminal discoveries ofMYD88 andCXCR warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) mutations in WM cells, our understanding of the disease biology and treatment has improved. The development of a new class of agents, Bruton tyrosine kinase inhibitors (BTKi), has substantially impacted the treatment paradigm of WM. Herein, we review the current and emerging BTKi and the evidence for their use in WM.Recent FindingsClinical trials have established the role of covalent BTKi in the treatm...
Source: Current Hematologic Malignancy Reports - March 27, 2024 Category: Hematology Source Type: research

Use of Vonicog Alpha and Acquired von Willebrand Syndrome, a New Approach: A Case Report
Hamostaseologie. 2024 Mar 22. doi: 10.1055/a-2266-7984. Online ahead of print.ABSTRACTTherapeutic management of acquired von Willebrand syndrome (AVWS) can be challenging, particularly in cases of AVWS associated with monoclonal IgM such as Waldenström macroglobulinemia (WM) where several therapeutic options may be ineffective. Here, we describe the case of an 88-year-old patient who developed AVWS during follow-up for WM. The presence of a severe bleeding symptomatology not controlled by several therapies (plasma-derived von Willebrand factor, plasmapheresis) led us to introduce a supplementation with recombinant von Wil...
Source: Hamostaseologie - March 22, 2024 Category: Hematology Authors: Adeline Blandini ères Sophie Combe No émie Chanson Olivier Lambotte C écile Lavenu-Bombled Source Type: research

Enhancing Plasmapheresis Efficacy in Waldenstrom Macroglobulinemia: Overcoming Circuit Clotting Challenges
Semin Dial. 2024 Mar 20. doi: 10.1111/sdi.13206. Online ahead of print.NO ABSTRACTPMID:38506146 | DOI:10.1111/sdi.13206 (Source: Seminars in Dialysis)
Source: Seminars in Dialysis - March 20, 2024 Category: Urology & Nephrology Authors: Urvashi Khan Sourabh Sharma Pallavi Prasad Anupam Agarwal Ankur Jain Aditi Jain Himanshu Verma Source Type: research